Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

mber 31, 2012 was $46.2 million, or $0.66 and $0.62 income per basic and diluted earnings per share, respectively, compared to non-GAAP net income of $58.6 million, or $0.85 and $0.82 income per basic and diluted earnings per share, respectively for the quarter ended December 31, 2011.

Revenue for the six months ended December 31, 2012 was $160.7 million compared to $77.9 million for the six months ended December 31, 2011. Revenue for the quarter ended December 31, 2012 was $58.0 million compared to $77.9 million for the quarter ended December 31, 2011. Revenue for the quarter ended December 31, 2012 consisted primarily of $50.0 million of milestone revenue due to the Company's achievement of one clinical milestone in connection with the Company's collaboration and license agreement (the "Agreement") with Janssen Biotech, Inc. and its affiliates ("Janssen") and $5.0 million of license revenue related to the Company's license agreement with Novo Nordisk A/S under which Novo Nordisk A/S acquired the exclusive worldwide rights for the Company's small molecule Factor VIIa inhibitor, PCI-27483, in a restricted disease indication outside of oncology.

To date, the Company has received three milestone payments from Janssen of $50 million each, totaling $150 million, under the Agreement. The Company may receive up to an additional $675 million in development and regulatory milestone payments, however, clinical development entails risks and the Company has no assurance as to whether or when the milestone targets might be achieved.

The Agreement with Janssen includes a cost sharing arrangement for certain development activities. In general Janssen is responsible for approximately 60% of development costs and the Company is responsible for 40% of development costs. The Agreement with Janssen also provides for a $50 million annual cap of the Company's share of development costs and pre-tax commercialization losses for each calendar year. Under the Agreeme
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... (PRWEB) November 17, 2014 RPS ... diagnostic tests – today announces its third annual ... Prevention’s (CDC) Get Smart About Antibiotics Week from ... is a national campaign designed to highlight the ... departments, and non-profit and for-profit partners to provide ...
(Date:11/18/2014)... (PRWEB) November 17, 2014 pH measurement ... processes across the pharmaceutical, chemical, and food and beverage ... so important, and how do pH sensors work? METTLER ... assist those in process industries with these questions and ... pH measurement in the process industries. The actual sensor, ...
(Date:11/18/2014)... (PRWEB) November 18, 2014 Alanda ... and Transparency Reporting solutions, announced today that a ... using its Consummate Provider™ solution in both the ... a Global, SaaS based, Data Quality remediation portal, ... their third party Providers improve their ability to ...
(Date:11/18/2014)... FL (PRWEB) November 18, 2014 Brothers ... announced the launch of PAWSitively Curing Cancer, Inc ... This new 501(c) (3) non-profit organization is dedicated to ... donated goes directly to the University of Florida ... partner with PAWSitively Curing Cancer as the recipient of ...
Breaking Biology Technology:RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3pH Guide from METTLER TOLEDO Explains Measurement, Theory and Practice of pH Applications 2Alanda Software Completes Successful Implementation of Global Data Quality & Vendor Management Solution for Top Tier Global Biopharmaceutical Company 2PAWSitively Curing Cancer, Inc. Launched By Two Children for National Pet Cancer Awareness Month 2PAWSitively Curing Cancer, Inc. Launched By Two Children for National Pet Cancer Awareness Month 3
... - Physicians Welcome New Option for Potentially ... Rapidly Bactericidal Mode of Action The ... both,methicillin-sensitive and resistant Staphylococcus aureus (MSSA and ... endocarditis) has been announced today by Novartis,Pharmaceuticals ...
... Sept. 12 Edwards Lifesciences,Corporation (NYSE: EW ... to,treat advanced cardiovascular disease, today announced its $5 ... Engineering at the,University of California, Irvine to establish ... new center is focused,on researching and developing the ...
... GPRO ) announced today that the Company will ... San Francisco on September,18, 2007 at approximately 2:30 p.m. ... to be webcast live and may be accessed,through a ... http://www.gen-probe.com . The webcast will be available for ...
Cached Biology Technology:New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA 2New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA 3New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA 4Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology 2Gen-Probe to Webcast Presentation at Bank of America's 37th Annual Investment Conference 2
(Date:11/4/2014)... OXFORD, England , November 4, 2014 ... expansion and vertical market growth   Fuel3D ... it has closed a funding round totaling $6.4 million (£4 ... (£1.6 million) funding secured earlier this year and paves the ... product in 2015. The funding round was led ...
(Date:11/3/2014)... Research and Markets has announced the addition of ... Companies" to their offering. This report ... already started to play an important role in the practice ... fashioned bone marrow transplants. Role of cells in drug discovery ... part of medical practice. Stem cells are discussed ...
(Date:11/3/2014)... Researchers from Australia report that low birth weight and ... (OA)-related hip replacements in adulthood. Findings published in the ... & Research , indicate that low birth weight and ... arthroplasty due to OA as adults. , According ... of 25 are diagnosed with clinical OA. Symptoms of ...
Breaking Biology News(10 mins):Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3Preterm, low birth-weight babies may need new hips in adulthood 2
... sea levels in the centuries to come? Are we destroying ... oceans on the rise? Can aquaculture be environmentally sustainable? And ... coastal fisheries? , Most importantly, what can governments, industry and ... media are invited to join leading international researchers and government ...
... the winner of the 2006 David Horrobin Prize for ... Nurture Assumption and No Two Alike, the article, "Parental ... human hairlessness and skin color" was judged to best ... launched in 2004, is awarded annually and named in ...
... the onset of type 1 diabetes in mice prone ... receptor on the surface of immune T-cells. According to ... the January issue of the journal Diabetes, have significant ... , More than 700,000 Americans have type 1 diabetes, ...
Cached Biology News:Are we killing the world's oceans? 2Why aren't humans furry? Stone-Age moms could be the answer 2Antibody therapy prevents type 1 diabetes in mice 2
... Captivate magnetic separator for ... used in conjunction with the ... C-21476) or other magnetic particles ... 96-well microplates. Cell Biology Cell ...
ANTI L-DOPA...
MAb to Hu-IFN-Gamma RC2 (CD118), NON-Neutralizing, Clone MMHGR-2 Binds to but does not neutralize human interferon gamma receptor...
RABBIT ANTI SRC-RSV...
Biology Products: